{"filings":[{"id":1120956,"accession_number":"0001104659-26-075451","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2026-06-18T12:21:16+00:00","items":["5.07"],"status":"ready","headline":"Bicycle Therapeutics shareholders approve all proposals at 2026 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["98.64% of shares represented; all 9 proposals passed with large majorities.","Felix Baker re-elected with 46.2M for vs 3.4M against; Hervé Hoppenot re-elected with 49.3M for.","Advisory vote on executive compensation passed: 48.7M for, 0.8M against.","Ratification of PwC as auditor for FY2026 passed: 49.4M for, 0.2M against.","Directors' remuneration policy approved: 48.2M for, 1.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584079,"accession_number":"0001104659-26-065231","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2026-05-21T21:05:25+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics reports positive Duravelo-2 mUC data with lower toxicity vs SOC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zelenectide + pembrolizumab: 58% confirmed ORR (15/26) at optimal dose in first-line mUC; 62% with later response.","Low adverse events: peripheral neuropathy 33%, skin reactions 17%, no Grade 4/5; only 1 discontinuation due to AE.","Updated Duravelo-1: median PFS 13.0 months in cisplatin-ineligible patients on zelenectide + pembrolizumab.","Further Phase 2 Duravelo-2 data from randomized trial expected in 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95269,"accession_number":"0001104659-26-052107","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics Q1 2026 net loss $60.8M, restructures, cuts 30% staff","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $60.8M ($0.87/sh) flat YoY; collaboration revenue dropped to $0.9M from $10.0M.","Cash $559.5M at March 31, 2026; expects runway into 2030 after cost cuts.","Workforce reduced ~30%; annual operating expenses expected to drop ~50%.","Duravelo-2 (zelenectide) converted to randomized Phase 2; Duravelo-3/4 trials discontinued.","Phase 2 trial of nuzefatide in pancreatic cancer started; first patient dosed April 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":887000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95268,"accession_number":"0001104659-26-045198","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics: nuzefatide 40% ORR in EphA2+ mUC; Phase 2 PDAC trial dosed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nuzefatide + nivolumab in 14 mUC patients: 40% ORR in EphA2+ tumors; 100% ORR (3/3) in MMAE-naïve EphA2+ tumors.","Preferred monotherapy dose identified as 8mg/m2 Q2W; first patient dosed in Phase 2 trial for 2L+ pancreatic ductal adenocarcinoma.","Human imaging data with EphA2 BIA detected PDAC metastases in 15/18 patients; validates EphA2 as a novel target.","No Grade ≥3 TRAEs of clinical interest with combination; differentiated safety profile vs other EphA2-targeted agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108197,"accession_number":"0001104659-26-028954","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics reports FY2025 results; deprioritizes lead drug zelenectide, plans 30% workforce cut","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deprioritizes zelenectide in mUC; converts Duravelo-2 to randomized Phase 2 after regulatory feedback says trial design no longer acceptable for approval.","Proposes ~30% workforce reduction; expects 50% annual opex savings; cash runway extended into 2030.","Appoints Jennifer Perry as COO; Alistair Milnes as CCDO. Perry receives $550K base salary, 50% bonus target.","Cash $628.1M at Dec 31, 2025 vs $879.5M at Dec 31, 2024; FY2025 net loss $219M ($3.16/sh).","Enters 15-year contract with UK Nuclear Decommissioning Authority for reprocessed uranium supply for radioconjugates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108196,"accession_number":"0001104659-26-009501","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bicycle Therapeutics appoints Travis Thompson as CFO, succeeding Alethia Young","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Travis Thompson appointed CFO effective Jan 29, 2026; previously SVP & Chief Accounting Officer since June 2023.","Thompson receives $500K base salary, 50% target bonus, and 58,000 option shares under 2020 Equity Plan.","Alethia Young steps down as CFO; remains in interim role through Apr 29, 2026, then as consultant for up to 3 years.","Young eligible for 9 months severance, full 2025 bonus, pro-rated 2026 bonus, and 9 months COBRA.","Thompson has no family relationships or related-party transactions with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108195,"accession_number":"0001104659-26-002706","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics outlines 2026 milestones; zelenectide pevedotin dose selection & approval pathway update in Q1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dose selection from Phase 2/3 Duravelo-2 trial and approval update for zelenectide pevedotin in mUC expected in Q1 2026","Additional EphA2 human imaging data for radiopharmaceuticals pipeline planned for first half of 2026","Initial data from Phase 1/2 Duravelo-3 trial in NECTIN4-amplified breast cancer expected in second half of 2026","Financial runway expected into 2028 to support execution of clinical and strategic priorities"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124640,"accession_number":"0001104659-25-104004","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics Q3 net loss $59.1M; lead drug regulatory update delayed to Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $59.1M ($0.85 per share) vs $50.8M ($0.74) in Q3 2024; R&D expenses up 21% to $58.4M.","Cash $648.3M (down from $879.5M at Dec 2024); additional $38.2M R&D tax credit received Oct 2025; runway into 2028.","Dose selection for zelenectide pevedotin Duravelo-2 trial and potential approval pathway update expected Q1 2026.","Strengthened Board with appointments of Charles Swanton, Roger Dansey, and Hervé Hoppenot.","BT5528 and BT7480 combination data presentations pushed to H1 2026; initial BRC EphA2 human imaging data expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":24631000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141316,"accession_number":"0001104659-25-088238","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics appoints Roger Dansey and Hervé Hoppenot to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Roger Dansey, M.D. (ex-Pfizer/Seagen) and Hervé Hoppenot (ex-Incyte/Novartis) joined the board effective Sep 8, 2025.","Board expanded from 8 to 10 members; Dr. Dansey serves as Class III director, Mr. Hoppenot as Class I director.","Both are independent; Dr. Dansey will serve on Scientific and Nominating/Governance committees, Mr. Hoppenot on Audit and Compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141315,"accession_number":"0001104659-25-075435","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics Q2 net loss widens to $1.14/share; cuts workforce 30% to extend runway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $79.0M ($1.14/share) vs $39.8M ($0.77) a year ago; R&D spend rose 77% to $71.0M.","Cash $721.5M at June 30, down from $879.5M at Dec 31; company expects runway through 2028 after cost realignment.","Workforce reduction of ~30% announced; Duravelo-5 trial paused while Duravelo-4 (NECTIN4-amplified NSCLC) enrolling.","Charles Swanton appointed to Board and Scientific Committee; new Research & Innovation Advisory Board formed.","Key catalyst: FDA meeting planned 4Q 2025 for zelenectide pevedotin accelerated approval pathway in mUC."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":12897000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159130,"accession_number":"0001104659-25-060316","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bicycle Therapeutics AGM results: all proposals pass, equity plan amendment sees 22.4% opposition","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected director Alessandro Riva: 40.0M for, 9.1M against (18.5% opposed).","Advisory 'say-on-pay' passed with 47.3M for, 1.7M against.","Ratified PwC as US auditor: 49.1M for, 41K against.","Approved amendment to 2020 Equity Incentive Plan: 38.1M for, 11.0M against (22.4% against).","All ordinary resolutions, including re-appointment of UK auditors and adoption of 2024 accounts, passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159129,"accession_number":"0001104659-25-043014","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics Q1 net loss $60.8M; cash $793M; Duravelo-3 trial recruiting","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $60.8M ($0.88 per share) vs $26.6M ($0.62) in Q1 2024; R&D expense $59.1M (+69% YoY).","Cash and equivalents $793.0M as of March 31, 2025, down from $879.5M at Dec 31, 2024; runway into 2H 2027.","Phase 1/2 Duravelo-3 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer open and recruiting.","Felix J. Baker to succeed Pierre Legault as Board chairman; Legault and Richard Kender retiring at June 17 AGM.","2 abstracts accepted for 2025 ASCO; dose selection for Duravelo-2 in mUC on track for 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":9977000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159128,"accession_number":"0001104659-25-040625","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics presents positive MT1-MMP imaging data from 12 solid tumor patients at AACR 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Data from 12 patients validate MT1-MMP as cancer target; BRC tracer showed uptake in primary tumors and metastases.","In lung cancer patient, MT1-MMP-PET showed BRC uptake in primary tumor (SUVmax 6.0) and bone metastases (SUVmax 7.9).","In breast/bladder cancer patient, MT1-MMP-PET revealed higher uptake than CT; IHC confirmed MT1-MMP expression in tumor.","Second BRC molecule targeting EphA2: initial human imaging data expected 2H 2025; company-sponsored trials planned for 2026.","Overall, 12 of 14 patients imaged successfully; results support radiopharmaceutical therapy potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177582,"accession_number":"0001104659-25-028531","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics appoints Alessandro Riva to board, names Felix Baker chairman, promotes Eric Westin to CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pierre Legault and Richard Kender to retire from board after AGM June 17, 2025; Felix Baker to become chairman.","Alessandro Riva joins board and scientific committee; receives annual cash $60k, option 25k shares, RSU 12.5k shares vesting over 3 years.","CDO Santiago Arroyo resigned March 24; separation includes pro-rated 2025 bonus, COBRA to May 2025; consulting fee $12k/yr, equity continues vesting.","Eric Westin promoted to CMO; Jim MacDonald-Clink promoted to SVP head of business development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177581,"accession_number":"0001104659-25-023934","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Bicycle Therapeutics sets June 17, 2025 for annual meeting; announces proposal deadlines","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2025 Annual General Meeting set for June 17, 2025; location and time in proxy statement.","Rule 14a-8 shareholder proposals must be received by March 31, 2025.","Non-proxy proposals and universal proxy notices due by April 18, 2025.","UK Companies Act resolutions from qualifying shareholders due by May 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177580,"accession_number":"0001104659-25-016709","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics reports Q4/FY24 net loss $169M; cash $879.5M; zelenectide pevedotin shows 65% ORR in mUC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $879.5M as of Dec 31, 2024, providing runway into 2H 2027.","Net loss $169.0M ($2.90 per share) for FY2024 vs $180.7M ($5.08 per share) in FY2023.","Phase 1 Duravelo-1: 65% ORR (13/20) for zelenectide pevedotin + pembrolizumab in first-line mUC; no Grade 4/5 TRAEs of interest.","FDA Fast Track granted for zelenectide pevedotin in NECTIN4-amplified TNBC and NSCLC; new Phase 1/2 trials planned in 2025.","R&D expenses $173.0M in FY2024, up from $156.5M in FY2023, driven by zelenectide pevedotin development."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":35275000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177579,"accession_number":"0001104659-25-003026","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics reports 65% ORR in Ph1 combo zelenectide plus pembro in 1L mUC; outlines 2025 milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated Phase 1 Duravelo-1 data: 65% ORR (13/20 evaluable) in 1L cisplatin-ineligible mUC; 50% confirmed ORR.","Median duration of response not yet mature; 12 patients remain on treatment at data cut-off (Jan 3, 2025).","No Grade 4/5 TRAEs of clinical interest; no patients withdrew due to zelenectide TRAEs; low-grade peripheral neuropathy, skin/eye events.","Cash and equivalents $890.9M as of Sept 30, 2024; financial runway into 2H 2027.","2025 milestones: Phase 2/3 Duravelo-2 dose selection data in 2H; initiate Phase 1 trials in NECTIN4-amplified breast, lung, and multi-tumor cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194291,"accession_number":"0001104659-24-128241","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics Reports Positive Zelenectide Pevedotin Data in Multiple Cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zelenectide pevedotin plus pembrolizumab showed 60% ORR in 22 first-line cisplatin-ineligible mUC patients.","Breast cancer patients with NECTIN4 gene amplification had 62.5% ORR (5/8) vs. 14.3% in all evaluable patients.","NSCLC patients with NECTIN4 gene amplification achieved 40.0% ORR (2/5); no responses in non-amplified patients.","Company plans Phase 1/2 trials in NECTIN4-amplified breast, lung, and other cancers in 2025.","Dose selection and topline data from Phase 2/3 Duravelo-2 trial expected in 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194290,"accession_number":"0001104659-24-112848","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics reports Q3 net loss $50.8M; strong cash $890.9M; 45% ORR for zelenectide pevedotin","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $50.8M ($0.74/shr) in Q3 2024 vs $49.9M ($1.26/shr) in Q3 2023; R&D spend $48.3M, up from $39.9M.","Cash $890.9M as of Sep 30, 2024, up from $526.4M at Dec 31, 2023; expects cash runway into 2H 2027; $31.7M UK tax credit received Oct 2024.","Zelenectide pevedotin (Nectin-4 BTC) monotherapy: 45% ORR in mUC (n=38), median DOR 11.1 months; differentiated safety profile; Phase 2/3 Duravelo-2 enrolling.","BT5528 (EphA2 BTC) monotherapy: 45% ORR in mUC at 6.5 mg/m2 Q2W (n=11); low peripheral neuropathy rates; combo with nivolumab expected 2025.","First human imaging data for BRC targeting MT1-MMP validates target; selected EphA2 as second BRC target; signed LOI with Eckert & Ziegler."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":31567000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194289,"accession_number":"0001104659-24-110749","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"First human imaging data validate MT1-MMP BRC radiopharmaceutical potential; strategy outlined","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First human PET/CT data for gallium-68-labelled MT1-MMP BRC show tracer uptake in lung cancer primary and metastases consistent with FDG imaging.","Preclinical data demonstrate BRC biodistribution optimized to maintain high tumor uptake while significantly reducing kidney retention.","Company selects EphA2 as second BRC target; signs letter of intent with Eckert & Ziegler for isotope supply and manufacturing.","CEO Kevin Lee highlights strategy to pursue novel targets with first-in-class radiopharmaceuticals using Bicycle platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210619,"accession_number":"0001104659-24-101202","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics reports positive ESMO 2024 data: 45% ORR for zelenectide pevedotin in mUC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zelenectide pevedotin monotherapy in mUC: 45% ORR (38 evaluable patients), 11.1 months median duration of response.","BT5528 in mUC: 45% ORR in 6.5 mg/m² Q2W expansion cohort; EphA2 expression correlates with response.","Low treatment-related peripheral neuropathy: 28% with zelenectide, 19% with BT5528; no Grade ≥3 events.","BT7480 in advanced solid tumors: favorable safety, 13 of 39 patients stable disease, 2 unconfirmed PRs in cervical cancer.","Global Phase 2/3 Duravelo-2 registrational trial for zelenectide pevedotin in mUC is enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210618,"accession_number":"0001104659-24-086085","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics Q2 net loss $39.8M; cash $961.4M after $555M PIPE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $39.8M ($0.77 loss per share) vs $42.6M ($1.41 loss per share) in Q2 2023; R&D expense $40.1M.","Cash and cash equivalents $961.4M as of June 30, 2024, up from $526.4M at Dec 31, 2023, after $555M PIPE financing.","Pipeline focused on zelenectide pevedotin (BTC) and BT5528; four abstracts accepted for ESMO 2024.","Jennifer Perry promoted to CSO & head of commercial; Nick Keen transitions to advisor; new Clinical Advisory Board formed.","Repaid $31.9M Hercules loan in July 2024 ahead of maturity; financial runway extended into 2H 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":28891000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210617,"accession_number":"0001104659-24-078976","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Bicycle Therapeutics terminates $30M Hercules loan, repays $31.9M total","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $30.0M principal plus $1.5M end-of-term charge and $0.3M prepayment fee, total $31.9M.","Used cash on hand to settle all amounts; loan was scheduled to mature July 1, 2025.","Loan bore interest at prime + 4.55% (min 8.05%, max 9.05%); secured by personal property except IP.","All security interests terminated and released upon repayment.","Voluntary termination reduces debt obligations; collateral released."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228967,"accession_number":"0001104659-24-072828","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics registers 37.7M shares for resale by selling securityholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed prospectus supplement to resell up to 37,656,764 ordinary shares (each represented by one ADS).","Shares are already outstanding; no new issuance or dilution from the company.","Legal opinion from Cooley (UK) LLP regarding share validity filed as exhibit.","Registration covers secondary resale only; no change in company's operations or guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228971,"accession_number":"0001104659-24-064716","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics raises ~$555M in private placement of 25.9M ADSs at $21.42; cash runway into H2 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 25,933,706 ADSs (and non-voting ordinary shares in lieu) at $21.42/share for gross proceeds of ~$555M.","Closing expected May 28, 2024; proceeds will boost cash to ~$1.0B, extending runway into second half of 2027.","Offering conducted as private placement under Section 4(a)(2) and Rule 506 of Regulation D.","Company to file a resale registration statement within 30 calendar days after closing or 15 business days if Form S-3ASR is effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228970,"accession_number":"0001104659-24-062503","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bicycle Therapeutics shareholders approve all 11 proposals at 2024 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Kevin Lee (36.4M for) and Jose-Carlos Gutierrez-Ramos (35.0M for) re-elected.","Advisory vote on executive compensation passed with 36.2M for, 1.2M against.","Ratification of PwC as US and UK auditors approved with ~37.4M for each.","Share allotment authorization and pre-emption rights disapplication passed with >32M for each.","New articles of association adopted with 37.4M for, 15,138 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228969,"accession_number":"0001104659-24-055981","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics Q1 net loss narrows to $26.6M; cash $457M; Phase 2/3 trial initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $457.0M as of Mar 31, 2024, down from $526.4M at Dec 31, 2023.","Net loss of $26.6M ($0.62 per share) vs $39.1M ($1.30) in Q1 2023; improvement helped by $8.2M retroactive UK R&D tax credits.","R&D expenses rose to $34.9M from $32.2M YoY, driven by BT8009 clinical program costs.","Initiated Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer; enrollment ongoing.","Mike Hannay promoted to Chief Product and Supply Chain Officer; multiple clinical data readouts expected in 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":19530000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228968,"accession_number":"0001104659-24-048576","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics appoints Felix Baker to board; Jordan resigns, becomes consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Veronica Jordan resigned as director April 17; will serve as consultant at GBP 12,000/yr for 2-year term, equity continues vesting.","Felix J. Baker appointed as Class I director effective April 18; will sit on Nominating and Scientific committees.","BBA Funds (Baker's affiliates) obtained registration rights for resale of ordinary shares/ADSs; company to file registration within 60 days of demand.","BBA Funds hold >10% of outstanding shares; Baker is a managing member of Baker Bros. Advisors GP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247594,"accession_number":"0001104659-24-025196","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics Q4 net loss $49.1M; cash $526.4M; BT8009 Phase 2/3 trial recruiting","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $49.1M ($1.16/share) in Q4 2023 vs $30.0M prior year; full year loss $180.7M ($5.08).","Cash $526.4M as of Dec 31, 2023, up from $339.2M; financial runway expected into 2026.","BT8009 Phase 2/3 Duravelo-2 registrational trial for metastatic urothelial cancer now active and recruiting.","BT8009 showed 38% objective response rate in EV-naïve mUC patients; differentiated safety profile.","Stephen Sands appointed to Board; former chairman of Lazard's Global Healthcare Group, serves on Audit and Strategic Committees."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":26976000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265053,"accession_number":"0001104659-23-125870","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics reports 38% ORR for BT8009, 39% ORR for BT5528 in mUC; plans Phase 2/3 trial in Q1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BT8009 showed 38% ORR in 26 EV-naïve mUC patients; median duration of response 11.1 months; zero severe peripheral neuropathy.","BT7480 demonstrated two unconfirmed partial responses in cervical cancer and three prolonged stable disease (≥7 months).","BT5528 achieved 39% ORR in 18 mUC patients; median DOR 4 months; no bleeding events observed.","Plans to initiate Phase 2/3 Duravelo-2 registrational trial for BT8009 in mUC in Q1 2024.","Next-generation Bicycle conjugates in development; BRC imaging data expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265052,"accession_number":"0001104659-23-113576","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics Q3 net loss $49.9M; FDA aligns on BT8009 Phase 2/3 trial for bladder cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $49.9M ($1.26/share) vs $28.3M ($0.96/share) in Q3 2022; R&D expenses rose to $39.9M.","Cash $572.1M as of Sep 30, 2023, up from $339.2M at Dec 31, 2022, including $215.1M net from July offering.","FDA aligned on Phase 2/3 registrational trial (Duravelo-2) for BT8009 in metastatic bladder cancer; starts Q1 2024.","BT8009 selected for FDA's CMC Development and Readiness Pilot (CDRP) program to expedite manufacturing.","Company plans R&D Day on Dec 14, 2023, to provide updates on BT8009, BT5528, and BT7480."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282246,"accession_number":"0001104659-23-099482","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics aligns with FDA on Phase 2/3 registrational trial for BT8009 in metastatic bladder cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA alignment reached on Duravelo-2 trial design; trial to begin Q1 2024.","Potential accelerated approval based on ORR, with PFS to confirm benefit.","Cohort 1: BT8009 + pembrolizumab in untreated metastatic bladder cancer.","Cohort 2: BT8009 monotherapy and combo in previously treated patients.","Discussions ongoing for confirmatory trial design in second-line-plus setting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282245,"accession_number":"0001104659-23-087020","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics Q2 net loss widens to $1.41/sh; cash >$600M after $230M raise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.6M ($1.41 loss per share) vs $26.8M ($0.90) a year ago; R&D expense doubled to $39.7M.","Cash $340.4M at June 30, 2023; pro-forma over $600M including $230M July offering and $45M Bayer upfront.","Strategic collaborations with Novartis (up to $1.7B milestones) and Bayer (up to $1.7B) for Bicycle radio-conjugates.","Appointed Alethia Young as CFO effective July 17, 2023; clinical updates on BT8009 expected in 2H23.","Preclinical data for Pb-BCY20603 BRC showed complete tumor regressions in rodent xenograft studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282244,"accession_number":"0001104659-23-080764","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics raises ~$187M net in public offering of 9.4M ADSs at $21.25/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 9,411,766 ADSs (or non-voting ordinary shares) at $21.25 per share; net proceeds ~$187.3M.","Underwriters granted 30-day option to purchase up to 1,411,764 additional ADSs.","Preliminary cash and cash equivalents of ~$340.4M as of June 30, 2023 (unaudited).","Offering expected to close July 17, 2023; 60-day lock-up for directors, officers and company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301387,"accession_number":"0001104659-23-074014","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bicycle Therapeutics appoints Alethia Young as CFO, replaces Lee Kalowski","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alethia Young appointed CFO effective ~July 17, 2023; Lee Kalowski resigned effective June 22, 2023.","Young previously CFO of Graphite Bio (GRPH) and biotech analyst at Cantor, Credit Suisse, Deutsche Bank.","Young receives base salary $480,000, bonus target 50%, signing bonus $100,000, option for 120,000 shares.","Travis Thompson appointed Chief Accounting Officer effective June 22, 2023; joined company in 2018.","No family relationships or related-party transactions between new officers and company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301386,"accession_number":"0001104659-23-071024","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bicycle Therapeutics shareholders pass all 10 proposals at 2023 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approximately 91.77% of outstanding ordinary shares voted; proposals passed with overwhelming support.","All three director nominees (Bourque, Jordan, Winter) re-elected; Winter received 27.2M votes for.","Advisory say-on-pay passed with 26.1M votes for vs. 1.97M against (93% approval).","PwC ratified as US auditor (28.0M for) and reappointed as UK statutory auditor.","Directors' remuneration policy approved with 26.1M for vs. 1.97M against (93% approval)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301385,"accession_number":"0001104659-23-065563","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics registers up to $150M additional ADS sale under ATM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on May 26, 2023, to sell up to $150M in ADSs via existing Sales Agreement with Cantor Fitzgerald and Oppenheimer.","Sales agents will receive 3% commission on gross proceeds; offering is an 'at the market' program under Rule 415.","Company is not obligated to sell any shares; sales at its discretion subject to market conditions.","The original Controlled Equity Offering agreement was dated June 5, 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301384,"accession_number":"0001104659-23-057986","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bayer and Bicycle Therapeutics enter $1.7B collaboration for radiopharmaceuticals; $45M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bicycle receives $45M upfront; total potential milestones up to $1.7B across up to three oncology targets.","Bayer fully funds all preclinical, clinical, manufacturing, and commercialization activities.","Bicycle eligible for mid-single to double-digit tiered royalties on commercialized products.","Closing subject to clearance under U.K. National Security and Investment Act 2021.","Collaboration uses Bicycle's bicyclic peptide technology to develop radioconjugates for undisclosed targets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301383,"accession_number":"0001104659-23-055781","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics Q1 net loss $39.1M; cash $293.8M; Novartis deal advances BRC pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $39.1M ($1.30 per share) vs $27.6M ($0.93 per share) in Q1 2022.","R&D expenses rose to $32.2M from $14.3M, driven by BT8009, BT5528, and TICA programs.","Cash $293.8M at March 31, 2023 (excluding $50M Novartis upfront); runway into 2025.","Entered Novartis collaboration for Bicycle radio-conjugates; eligible for up to $1.7B milestones.","BT8009 Phase I dose escalation showed median duration of response ~14 months in urothelial cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":4896000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301382,"accession_number":"0001104659-23-040523","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics appoints Dr. Arroyo as CDO, promotes Perry to SVP Commercial; CMO leaves","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Santiago Arroyo appointed Chief Development Officer effective March 31, 2023; formerly CMO at Momenta and Fulcrum.","Jennifer Perry promoted to Senior Vice President, Commercial; over 20 years pharma experience in oncology.","Dominic Smethurst, former Chief Medical Officer, has left the company; CEO thanked him for contributions.","Arroyo to oversee pipeline expansion and late-stage development; Perry to build commercial organization.","Company advancing oncology programs BT8009, BT5528, and BT7480 in the clinic."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321209,"accession_number":"0001104659-23-037376","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics enters Novartis collaboration for Bicycle radio-conjugates; $50M upfront, up to $1.7B milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bicycle Therapeutics receives $50M upfront from Novartis to discover Bicycle radio-conjugates for oncology targets.","Total potential milestones up to $1.7B, plus tiered royalties on commercial sales at high single to low double digits.","Novartis funds all preclinical/clinical development, manufacturing, and commercialization for BRCs.","Collaboration initially covers two targets; Novartis pays mid-teen million candidate selection fees per product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321208,"accession_number":"0001104659-23-026349","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics reports FY2022 net loss of $112.7M; cash $339.2M, runway into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.0M in Q4 2022 ($1.01/share) and $112.7M for FY2022 ($3.80/share), vs $18.0M and $66.8M in prior year.","Cash and equivalents $339.2M at Dec 31, 2022, down from $438.7M; expected to fund operations into 2025.","R&D expenses rose to $81.6M in FY2022 from $44.9M, driven by clinical programs for BT5528, BT8009, and TICA platform.","BT8009 granted FDA Fast Track Designation for urothelial cancer; Phase II expansion initiated with RP2Ds established.","BT5528 continues in dose expansion; BT7480 in dose escalation; pipeline updates expected later in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":14463000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321207,"accession_number":"0001104659-23-021008","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics announces Phase I BT8009 results: 50% ORR in urothelial cancer, well tolerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["50% overall response rate (ORR) and 75% clinical benefit rate in urothelial cancer at 5 mg/m2; one complete response.","Median duration of response estimated ~14 months; two of four responders remain on therapy as of Jan 2023.","Confirmed partial responses in NSCLC and breast cancer patients, both Nectin-4 positive.","Well tolerated: low rates of skin rash, neuropathy, pneumonitis; no Grade 3+ related events at 5 mg/m2.","BT8009 advancing into dose expansion (up to 66 patients) and combination trial with pembrolizumab planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321206,"accession_number":"0001104659-23-005586","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2023-01-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bicycle Therapeutics increases change-in-control severance for CEO, CFO, and CTO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Kevin Lee receives 24 months' base salary and benefits on change-of-control termination; subject to shareholder approval.","CFO Lee Kalowski and CTO Michael Skynner get 18 months' base salary and benefits on change-of-control termination.","Compensation committee approved amendments on Jan 17, 2023; CEO amendment pending AGM vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339326,"accession_number":"0001104659-22-115679","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BT8009 Phase II expansion first patient dosed; Phase I dose escalation complete","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase I dose escalation complete; RP2Ds: 5 mg/m2 weekly and 7.5 mg/m2 (2 on, 1 off) selected.","Confirmed RECIST responses in UC and NSCLC; median duration of response not yet reached.","First patient dosed in Phase II expansion; includes cohorts evaluating BT8009 with CPI.","Priority indication: first-line metastatic UC in cisplatin-ineligible patients combined with CPI.","Updated Phase I data from 49 patients to be presented at medical meeting in 1H 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339325,"accession_number":"0001104659-22-114205","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicycle Therapeutics reports Q3 net loss $28.3M; cash $361.5M; clinical pipeline progressing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.3M ($0.96 per share) vs $14.7M ($0.59) in Q3 2021.","Cash and equivalents $361.5M at Sep 30, 2022 ($438.7M Dec 31, 2021); runway into 2025.","R&D expenses $22.8M (up from $10.5M) driven by BT5528, BT8009, and platform costs.","Received $10M option fee from Genentech for expansion of immuno-oncology collaboration.","BT5528 showed 22% ORR in ovarian, 67% in urothelial; expansion enrollment on track for Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":11278000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356693,"accession_number":"0001104659-22-098037","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics reports BT5528 Phase I dose escalation results: ORR 22% in ovarian, 67% in urothelial cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Among 9 EphA2-positive ovarian patients, ORR 22% (1 CR, 1 PR), DCR 67%; median 4 prior therapies.","In 3 EphA2-positive urothelial patients, ORR and DCR 67% (2 PRs).","Safety differentiated from EphA2 ADCs: no treatment-related hemorrhage, low-grade neuropathy, rash, eye disorders.","RP2D established at 6.5 mg/m2 every other week; expansion cohorts for ovarian, urothelial, and basket cancers ongoing.","Enrollment ongoing in expansion cohorts of up to 56 patients; updates expected next year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356692,"accession_number":"0001104659-22-085864","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics reports Q2 net loss $26.8M, cash $372.8M; Genentech expands collaboration","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.8M ($0.90/share) vs $17.9M ($0.74) in Q2 2021, driven by higher R&D and G&A costs.","Cash $372.8M as of June 30, 2022, down from $438.7M; expected runway into 2025.","Genentech exercised option to expand immuno-oncology collaboration, triggering $10M payment to Bicycle in Q3 2022.","BT8009 Phase I interim data: 50% ORR in urothelial cancer at 5.0mg/m2 weekly; four of five responders on therapy >24 weeks.","Expansion cohorts of BT5528 Phase I/II trial initiated; BT7480 Phase I/II poster presented at ASCO 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":8238000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356691,"accession_number":"0001104659-22-080262","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2022-07-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics amends Hercules Capital loan, extends maturity to 2025, adds up to $75M borrowing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term Loan Maturity Date extended to July 1, 2025; Amortization Date moved to April 1, 2025.","Borrowers can request additional Term Loan Advances up to $75M aggregate (Tranche 3 up to $45M) before Dec 31, 2024, subject to lenders' approval.","Term Loan Interest Rate decreased to lesser of (i) greater of 8.05% or prime+4.55% and (ii) 9.05% per annum.","Existing loan agreements ratified; security interests reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356690,"accession_number":"0001104659-22-079143","cik":1761612,"company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","form_type":"8-K","filed_at":"2022-07-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicycle Therapeutics expands Genentech immuno-oncology collaboration; receives $10M option exercise payment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Genentech exercised second option to add a new program to the existing 2020 collaboration, triggering a $10M payment to Bicycle.","First expansion option under the same agreement was exercised in October 2021, also for $10M.","Collaboration covers discovery and preclinical development of novel Bicycle-based immunotherapies against multiple targets.","Bicycle's wholly owned oncology pipeline, including its immuno-oncology candidates, is not part of the collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":318561121.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-07-12T23:59:59+00:00|356690"}